A Recurring Theme: A Rare Case of Pembrolizumab-induced Acute Interstitial Nephritis.

Autor:	London J; Department of Internal Medicine, Long Island Community Hospital, USA., Bulancea S; Department of Internal Medicine, Long Island Community Hospital, USA., Shirazi I; Department of Internal Medicine, Long Island Community Hospital, USA., Oriuwa V; Department of Internal Medicine, Long Island Community Hospital, USA., Bolotova O; Department of Nephrology, Long Island Community Hospital, USA., Tharayil Z; Department of Internal Medicine, Long Island Community Hospital, USA.
Jazyk:	angličtina
Zdroj:	Journal of community hospital internal medicine perspectives [J Community Hosp Intern Med Perspect] 2024 Jul 02; Vol. 14 (4), pp. 65-67. Date of Electronic Publication: 2024 Jul 02 (Print Publication: 2024).
DOI:	10.55729/2000-9666.1362
Abstrakt:	Pembrolizumab is utilized in the treatment of multiple different malignancies, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, renal cell carcinoma, endometrial cancer, and more. Pembrolizumab is an immune checkpoint inhibitor that inhibits the programmed cell death-1 (PD-1) signaling pathway. Despite its benefits in treating multiple cancers, there are many reported adverse effects of Pembrolizumab affecting various organ systems; rarely it can cause acute interstitial nephritis (AIN). We present the case of a 79-year-old male with metastatic retroperitoneal squamous cell carcinoma who was found to have recurrent acute interstitial nephritis after pembrolizumab therapy. Competing Interests: Conflict of interest: There are no conflict of interests to report. (© 2024 Greater Baltimore Medical Center.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu